Rare Disease Report

Hearing Loss in Cisplatin Treated Patients

APRIL 30, 2017
David Freyer, DO

David Freyer, DO, of the Children's Hospital of Los Angeles and professor of pediatrics at Keck School of Medicine, University of Southern California, explains the mechanisms by which hearing loss can occur in children (and adults) treated with cisplatin, a chemotherapy agent commonly used in oncology. 
As Dr Freyer explains in this video taken during the ASPHO's 30th Annual Meeting in Montreal, Canada, the ototoxicity can be particular harmful to the survivors of pediatric cancer.
Sodium thiosulfate (STS) is a water-soluble thiol compound and acts as a chemical reducing agent. Administration of STS may protect against platinum-induced ototoxicity, as it has been shown in animal models and in patients.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.